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At least 120 non-olfactory G protein-coupled receptors in the human genome are ”orphans” for 
which endogenous ligands are unknown, and many have no selective ligands, hindering 
elucidation of their biological functions and clinical relevance. Among these is GPR68, a proton 
receptor that lacks small molecule modulators for probing its biology. Yeast-based screens against 
GPR68 identified the benzodiazepine drug lorazepam as a non-selective GPR68 positive allosteric 
modulator. Over 3000 GPR68 homology models were refined to recognize lorazepam in a putative 
allosteric site. Docking 3.1 million molecules predicted new GPR68 modulators many of which 
were confirmed in functional assays. One potent GPR68 modulator—ogerin– suppressed recall in 
fear conditioning in wild-type, but not in GPR68 knockout mice. The same approach led to the 
discovery of allosteric agonists and negative allosteric modulators for GPR65. Combining 
physical and structure-based screening may be broadly useful for ligand discovery for 
understudied and orphan GPCRs.
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G protein-coupled receptors (GPCRs)–the largest family of proteins encoded in the human 
genome–transduce signals for the most diverse endogenous ligands of any receptor family. 
Correspondingly, GPCRs are the most productive drug targets, with over 26% of FDA-
approved drugs acting primarily through them. Astonishingly, of the 356 non-olfactory 
GPCRs, about 38% are understudied or “orphan” receptors whose physiological roles, and 
often endogenous ligands, remain unknown1. Given the central role of GPCRs in physiology 
and disease, and the high conservation of orphan GPCRs among organisms from worms to 
humans, understudied and orphan GPCRs are likely functionally and therapeutically 
important. Indeed, for the few GPCRs deorphanized since 20031,2 (http://www.iuphar-
db.org/latestPairings.jsp/), most have newly approved and investigational drugs1,3. As with 
kinases4, epigenetic proteins5, and proteases6, ligands specific for orphan GPCRs will 
illuminate their biology and provide new areas for therapeutic intervention.
A key impediment to GPCR deorphanization is uncertainty about the proteins through which 
they signal, making functional assays problematic1. This difficulty is increased by the 
diverse ligands that GPCRs recognize, which range from protons and photons, small 
neurotransmitters, lipids, to peptides and folded proteins. Thus, generic functional screens 
are difficult for orphan GPCRs–one neither knows what class of compounds to screen, nor 
how to screen for it, much less how to demonstrate relevance–thereby explaining the slow 
progress in determining their roles in signaling and in physiology3.
GPR68 (OGR1) exemplifies both the important roles these understudied and orphan 
receptors are thought to serve, and our difficulties in illuminating them. GPR68, together 
with GPR4, GPR65, and GPR132, form a family of proton-sensing GPCRs7. GPR68 
couples to multiple signaling pathways through Gq, Gs, G12/13, or Gi/o proteins7–10. GPR68 
is expressed in many tissues, and has been implicated in many processes11–16, but is most 
abundant in mouse cerebellum17 and hippocampus11 (http://www.brain-map.org/), implying 
yet-to-be identified roles in brain function. In acidic microenvironments, GPR68 appears to 
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regulate inflammatory processes in airway smooth muscle (ASM) and other cells18–20. 
Confoundingly, studies with GPR68 knockout (KO) mice uncovered only modest changes in 
these functions21,16,22. Although GPR68 has been reported to be activated by a family of 
isoxazoles15, their weak activity appears to be non-specific23,24 and could not be reproduced 
(Results). Thus, though GPR68 may have multiple roles, few of them are well-characterized 
by knockout and none are known in the CNS, where it is most highly expressed. Like other 
targets lacking small molecule reagents, GPR68 remains “pharmacological dark matter”1.
Here we describe an integrated experimental and computational approach to discover 
ligands that modulate GPR68. A lead compound that functions as a positive allosteric 
modulator (PAM) is demonstrated in vitro and in vivo, providing insights into GPR68 
physiology. Application of the same approach found allosteric agonists and negative 
allosteric modulators (NAMs) for a second understudied GPCR, GPR65, suggesting the 
approach may be broadly useful.
Yeast-based screen reveals GPR68 actives
In an initial campaign with selected orphan and understudied GPCRs, we modified an yeast 
assay system25 and screened a small library of approved drugs (http://
www.nihclinicalcollection.com/) (Supplementary Figure 1). We confirmed the known 
activity of short-chain carboxylic acids at the GPR41 and the GPR43 free fatty acid 
receptors (Extended Data Fig 1a–d), and that of zinc (Extended Data Fig 1e) and several 
other metals (Extended Data Fig 1f–k) on GPR39. The most striking result was the finding 
that lorazepam was an agonist at GPR68 (Figure 1).
Lorazepam–a benzodiazepine anxiolytic–activated GPR68 signaling, stimulating yeast 
growth by more than two-fold (Figure 1a). N-unsubstituted benzodiazepines were more 
efficacious than N-substituted benzodiazepines (Figure 1b–c, Supplementary Table 1) and 
activated the receptor at both pH 6.5 and 7.4 (Extended Data Fig 1l), with lorazepam most 
potently shifting the H+ concentration-response profile (Figure 1d and Extended Data Fig 
1m–p). The pH dependence of lorazepam’s activity suggested that it functions as a PAM of 
GPR68; lorazepam had no activity at the related receptors GPR4 or GPR65 (Extended Data 
Fig 2a–b). When profiled against a panel of CNS targets, lorazepam had substantial activity 
only at the GABAA receptor, its therapeutic target (Extended Data Fig 3).
Modeling the GPR68-lorazepam complex
Little improvement in activity or selectivity was achieved by testing lorazepam analogs. 
This observation, and the drug’s potent GABA-A receptor activity, led us to seek specific, 
optimizable molecules from computational docking screens of multi-million molecule 
libraries (Figure 2).
We generated 407 homology 3D models for GPR68 templated on the CXCR4 structure 
(29% sequence identity, Extended Data Fig 2f) and these were expanded by another 2,900 
models using elastic network modeling, which sampled backbone and loop conformations. 
Against each of the 3,307 models we computationally docked the active benzodiazepines, 
the over 446 inactives from the NCC library, and 176 property-matched decoy molecules26. 
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In each model, five candidate allosteric sites were docked against (Extended Data Fig 2g) 
based on the binding regions of aminergic GPCRs, the peptide and antagonist sites of 
CXCR4, and the muscarinic receptor allosteric site. Iterative cycles of modeling and 
optimization (Figure 2b–e) attempted to capture two aspects of ligand binding. First, the 
activity of the benzodiazepines as PAMs, and second the role of histidines 17, 84, 169 and 
269, which are thought to interact with one another in the inactive state, and move apart on 
protonation at lower pH values7. This cycle converged to a stable lorazepam docking pose 
(Figure 2f), and to its ranking first among the 622 decoy molecules. This strategy resembles 
previous ligand-guided docking27–29, although here the binding site was unknown. In its 
docked geometry, lorazepam hydrogen bonds with Glu160, Arg189, Tyr244, and Tyr268, 
and forms non-polar contacts with Trp77, Leu101, Phe173, His269, and Leu272 (Figure 2f).
To test the modeled lorazepam site, we mutated residues lining it (Figure 2f, Extended Data 
Fig 2e–f), Glu160, Arg189, and His269, and determined their roles in proton-mediated 
cAMP production and calcium release (Extended Data Fig 4). The H269F mutant right-
shifted proton-response curves in both assays7, while substitutions at Arg189 selectively 
abolished cAMP production. Different substitutions at Glu160 had varying effects at 
downstream signaling pathways – E160A left-shifted the proton-response curve and reduced 
cAMP production, but was inactive in calcium release, while the E160K and E160Q 
mutations had modest effects in both pathways (the mutants had little effect on expression, 
Extended Data Fig 4c). These substantial and differential effects on downstream coupling 
support a role for these residues in GPR68’s functions, and are consistent with the modeled 
binding site for lorazepam.
Seeking optimized PAMs, we computationally docked 3.1 million available lead-like 
molecules against the putative lorazepam site in GPR68. Overall, more than 3.3 trillion 
complexes were calculated and scored. From among the top 0.1% of the docking-ranked 
molecules, 17 were purchased for testing; along with their high docking ranks, these 
compounds recapitulated key interactions made by lorazepam in its docked model, were 
chemically diverse, and had high-scoring analogs (Supplementary Table 2).
Four of the docking hits increased cAMP production by about 1.5 fold over basal at pH 6.5 
(Figure 3a). Though none were as active as lorazepam, two compounds, ZINC4929116 and 
ZINC32587282 had hundreds of available analogs. These were docked against the GPR68 
model, and 25 were chosen for testing (Figure 3a, Supplementary Table 3). Thirteen had 
greater activity than lorazepam, and their pH-dependent potentiation activity clearly 
indicates allostery. Though dissimilar, lorazepam and ZINC67740571 dock to form many of 
the same interactions, with the addition of a new predicted hydrogen-bond to Glu160 from 
the hydroxyl of ZINC67740571 (Figure 2f, h, Extended Data Fig 2h).
Ogerin as a selective GPR68 PAM
Ten selected compounds were studied further in functional assays. According to the standard 
allosteric operational model30, all were GPR68 PAMs, lacking intrinsic activity but 
increasing agonist potency (α factor) for cAMP production by 1.9 to 8.2-fold, and increasing 
efficacy (β factor) from 1.1 to 5.6-fold (Supplementary Table 5). It is this ability to shift 
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concentration-response curves leftward and upward (Extended Data Fig 4b) that are the key 
characteristics of a PAM. ZINC67740571 had a much higher allosteric effect than 
lorazepam (Figure 3b vs Figure 1d, and Supplemental Table 8); we dubbed it “ogerin” (for 
OGR1 ligand).
Though ogerin and ZINC32547799 are close analogs (Figure 3a), each had distinct 
functional activities (Figure 4a, Extended Data Fig 4f–g) and docking poses (Figure 2f, 
Extended Data Fig 2h). Thus, the ortho-hydroxylmethyl group, which differentiates them, 
may play a key role in determining PAM activity, perhaps because of its ability to hydrogen-
bond with Glu160, which the meta-positioned hydroxylmethyl in ZINC32547799 cannot 
reach. The structure-guided mutants H269F and R189L responded to ogerin and 
ZINC32547799 differently (Figure 4a, Extended Data Fig 4f–g, and Supplementary Table 
6), supporting the modeled interactions with these residues. Strikingly, rather than 
activating, ogerin inhibited proton-mediated calcium release–a pathway-specific function 
rescued in R189L and H269F (Figure 4b, Extended Data Fig 4h–I, and Supplementary Table 
7). Meanwhile, ZINC32547799 had little effect on calcium release. To determine if fast 
kinetics affect the difference between cAMP measurement (under equilibrium) and calcium 
release (non-equilibrium), we also conducted phosphatidylinositol hydrolysis assays under 
equilibrium. Ogerin slightly potentiated proton activity here (Extended Data Fig 4j–k) while 
ZINC32547799 did not. Finally, ogerin had minimal PAM activity at the related proton-
sensing GPCRs, GPR4 and GPR65 (Extended Data Fig 2c–d). Ogerin appears to be a 
functionally selective GPR68 PAM for the agonist proton.
If the ogerin/GPR68 model is relevant, we should be able to leverage it for optimization. We 
designed a virtual library of over 600 ogerin analogs and docked each into the GPR68 model 
(Extended Data Fig 2h–i). Thirteen high-scoring analogs were synthesized, and three were 
more active than ogerin (Supplementary Table 9 and Extended Data Fig 6), including 1st and 
7th ranked compounds, the latter of which, C2, had the greatest allosteric effect, shifting 
proton response 3-fold further to the left than does ogerin, for an α-factor of 22 (Figure 3a–
c, and Supplementary Table 8). C2 differs from ogerin by addition of a methylene to the 
benzylamine side chain, which places the phenyl ring deeper into a modeled apolar pocket 
(Extended Data Fig 2i). The addition of one or two further methylenes in compounds C3 
and C4 (Figure 3a), conversely, reduced allostery (Supplementary Table 8 and Extended 
Data Fig 6f), consistent with reduced complementarity to the apolar pocket in the modeled 
complex.
To investigate ogerin specificity for GPR68 over unrelated targets, which might affect its 
usefulness as a biological probe, we first computationally screened ogerin and its analogs for 
off-targets using the SEA program31 against a panel of 2800 targets. These calculations 
revealed similarity between the GPR68 ligands and those of only three other GPCRs: the 
ghrelin and the adenosine A1 and A2A receptors. Subsequent physical profiling against 58 
GPCRs, ion channels, and transporters (Extended Data Fig 3) revealed that ogerin had 
moderate affinity at two GPCRs, 5-HT2B and the A2A receptor (Extended Data Fig 5h–i), 
the latter consistent with the SEA prediction.
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Intrigued by the association between the GPR68 PAMs and adenosine receptor antagonists, 
we computationally screened a library (http://www.tocris.com/dispprod.php?
ItemId=5386#.U_s5ZMVdUrU) of 1,120 reagents and drugs against the GPR68 ligands, 
again using SEA. SLV320, a selective adenosine A1 antagonist32, was predicted to be a 
GPR68 PAM and confirmed by a physical screen of the full library (SLV320 αβ=2.8) 
(Extended Data Fig 7 and Supplementary Table 8), as was a second adenosine receptor 
antagonist, CGH2466 (αβ=2.9), and tracazolate (αβ=3.4), a GABA-ergic drug that also 
antagonizes adenosine receptors33. Although CGH2466 has the lowest apparent binding 
constant (KB) of any GPR68 PAM (48 nM), its allostery is much lower than that of ogerin; 
additionally, like SLV320 and tracazolate, CGH2466 is a potent phosphodieseterase 
inhibitor (Extended Data Fig. 7) and had minimal activity in the presence of Ro 20-1724. 
This previously unknown cross-talk among the GPR68, adenosine and GABA receptor 
ligands (Extended Data Fig. 7d), along with their activities at phosphodiesterases, should be 
considered when evaluating the pharmacology of what have been considered specific probes 
and drugs.
Ogerin as a GPR68 probe
Given its activity and specificity, we sought to explore ogerin’s downstream signaling and 
its in vivo activity. In GPR68-expressing HEK293 cells we found that both ogerin and 
lorazepam activate the PKA and MAP kinase pathways (Extended Data Fig 8a), mimicking 
the low pH-induced signaling observed with GPR68 receptors in human ASM cells19. The 
activation of GPR68 in smooth muscle cells by extracellular acidification is linked to 
multiple downstream pathways and biological responses18,19,22,34–37, which a selective 
allosteric modulator, such as ogerin, may help to disentangle.
To investigate effects in behavior associated with modulation of the hippocampus, where 
GPR68 is highly expressed17, we evaluated GPR68 KO and WT mice in a learning and 
memory test, fear conditioning, in which the hippocampus plays important roles (Extended 
Data Fig 8, 11). In WT mice, ogerin attenuated contextual-based fear memory without 
effects on cue-based memory (Figure 4c–d). The magnitude of these effects is comparable to 
those of compounds targeting other hippocampus-expressed GPCRs38,39, and larger effects 
are rarely observed without surgical lesion of the hippocampus40. Crucially, administration 
of ogerin had no effect on memory retrieval in GPR68 KO mice (Figure 4c–d), indicating 
that ogerin’s in vivo effects are GPR68-dependent. Furthermore, the less active ogerin 
isomer, ZINC32547799, had no measurable effect on learning and memory in wild-type 
mice (Figure 4c–d and Extended Data Fig 8d–h). Ogerin’s effects thus support a role for 
GPR68 in hippocampal-associated memory.
General applicability of the approach
To explore the broader usefulness of this approach, we sought ligands for GPR65, another 
understudied pH-sensing receptor, which shares 37% sequence identity to GPR68. We found 
that a recently reported GPR65 agonist BTB0908941 is an allosteric agonist of GPR65 
(Figure 5d–e, and Extended Data Fig 10a). We used BTB09089 to anchor modeling of 
GPR65, generating 500 homology models templated on GPR68. The final docked GPR65-
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BTB09089 model resembles that of GPR68-ogerin, with several side-chain substitutions in 
the putative binding site (Figure 5a).
We docked the same 3.1 million compounds against the GPR65 model, purchasing 45 novel 
molecules for testing (Figure 5a–c, Supplementary Table 10). ZINC13684400 showed 
agonist activity of over 2 fold of basal at GPR65, with a potency of 500 nM, without 
measurable activity at control cells (Figure 5e, and Extended Data Fig 9). As with 
BTB09089, ZINC13684400 did not potentiate proton efficacy at GPR65 (Figure 5d), but 
acted as an allosteric agonist. To test the model, three residues modeled to interact with both 
BTB09089 and ZINC13684400, Arg187, Phe242, and Tyr272, were mutated, as was 
Asp153, which appears to only hydrogen-bond with ZINC13684400 (Figure 5b). R187L, 
F242A, Y272A reduced the activity of both compounds (Extended Data Fig 10f–g), while 
D153A had no effect on BTB09089 but much reduced the activity of ZINC13684400, 
consistent with the model. Several other docking hits inhibited GPR65 when the receptors 
were activated by protons or by BTB09089, including ZINC62678696 (Extended Data Fig 
10b–d). Unexpectedly, ZINC62678696 does not compete with BTB09089, as predicted, but 
rather acts as a BTB09089 NAM (Figure 5f), suggesting that the two molecules can bind to 
GPR65 simultaneously (Figure 5g).
Discussion
A combined empirical and structure-based approach discovered potent PAMs at the 
understudied receptor GPR68, and an allosteric agonist and NAMs for the understudied 
GPR65. This supports the approach’s usefulness for illuminating the “dark matter” of the 
GPCR-ome–the 38% of non-olfactory GPCR targets whose ligands and function are 
understudied or unknown1. Whereas truly high-throughput screens are impractical for 
targets of unknown function, lower-throughput screens are often feasible. Although the hits 
from such a screen may be unsuitable as probes, they can anchor computational screens for 
more optimized compounds. Correspondingly, we would not ordinarily expect docking to 
succeed against models of a target that shares only 29% sequence identity with its nearest 
template. By calculating several thousand models, and insisting that the relevant ones are 
those that prioritize active over inactive molecules, functionally relevant models are 
prioritized. The new ligands that emerged are specific for the target and one is active in vivo, 
supporting their use as chemical probe for the function of GPR68.
Pharmacologically, the most unexpected observation was the activity of GPR68 in learning 
and memory. Previous studies in GPR68 KO mice revealed only modest phenotypic 
changes21,16,22, none in higher brain function, even though GPR68 is most highly expressed 
in the brain. Ogerin transiently and reversibly reduced contextual-based fear memory in 
wild-type but not GPR68 KO mice, consistent with on-target activity in vivo. In hindsight, 
this is perhaps only accessible to chemical modulators, which can have PAM activities. 
Inhibitory genetic perturbations, such as knockouts or knockdowns, though crucial to 
demonstrating on-target activity through chemical genetic epistasis, cannot on their own 
reveal such activation-based modulation.
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Deorphanizing a receptor can also illuminate its off-target roles for known drugs. The 
observation that lorazepam and its primary metabolite, desmethyldiazepam, are GPR68 
PAMs may clarify several of the idiosyncratic effects of this widely-used anxiolytic. 
Lorazepam, uniquely among benzodiazepines, can treat catatonia, an effect hypothesized to 
involve an unknown secondary target42. GPR68 may have a role in this efficacy, as both 
drug and metabolite reach micromolar concentrations in plasma during treatment43.
Certain caveats bear airing. The combination of empirical and computational screens will 
not work for all orphan receptors. GPCRs that are poorly expressed or non-functional in 
yeast or transfected cells will be problematic, and some orphans will simply not recognize 
any of the molecules screened in the small empirical libraries. Also, some orphans will bear 
too little similarity to templates of known structure to support accurate modeling. Even those 
that do work will demand cycles of testing and optimization, which was crucial for both 
GPR65 and GPR68.
These cautions should not obscure the key observations from this study–that combining 
empirical and structure-based screening led to a probe molecule that reveals some of the 
functions of GPR68. The finding that ogerin potentiates GPR68 activation and downstream 
MAP kinase pathways, and previous observations that the receptor mediates airway 
inflammation, enables campaigns for GPR68 PAMs that may regulate respiratory 
inflammatory responses. Uniquely as PAMs, these compounds would have fidelity to the 
natural spatial and temporal activation of GPR68. Correspondingly, the role of GPR68 in 
anxiety offers a new route to treating this condition, and related CNS disorders, an area in 
need of new therapeutic modalities44. Methodologically, this approach may have broad 
application to illuminating the function of the “dark matter” of the genome, that still large 
area of pharmacology where targets are known, but function is hidden.
Online Methods
Chemicals, reagents, and cells lines
Chemicals and reagents used in this study, if not specified otherwise, were purchased from 
commercial sources (Sigma, Tocris, Fisher Scientific, or specified in Supplementary Tables 
of chemical structures) or synthesized as outlined in the supplementary information. 
HEK293 and HEK293 T cells were from ATCC.
Homology Modeling
The alignment for the construction of the GPR68 models was generated using 
PROMALS3D, and homology models were built with MODELLER 9v845, using the crystal 
structure of the chemokine CXCR4 receptor (PDB ID: 3ODU) as the template (Extended 
Data Fig 2f). This alignment was also used to generate 500 models of GPR65 directly from 
the final GPR68 model. The initial alignment included both human and mouse sequences of 
GPR68, as well as those of its closest homolog, GPR4. These were aligned against the 
whole human C-X-C chemokine receptor family. The alignment was manually edited to: 
remove the N- and C-termini that extended past the template structure, remove the 
engineered T4 lysozyme, and create different alignments of the flexible and non-conserved 
second extracellular loop (the final result is given in the provided alignment, Extended Data 
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Fig 2f). 407 models were built directly based on the CXCR4 crystal structure, using 
MODELER-9v845, while five more were built from each of 580 elastic network models 
(ENMs), produced by the program 3K-ENM46, for a total of 3,307 models built during each 
iterative round of model refinement. Models with constraints between pairs of extracellular 
His residues (His17-His169, His17-His269, His17-His84, His84-His169) to mimic the 
inactive state of the protein were generated by enforcing a distance constraint of 2.7 Å 
between the imidazole nitrogens, with a standard deviation of 0.1 Å. Confirmed actives and 
analogs using CXCR4-based model had neither agonist nor antagonist activity at CXCR4 
receptors (Extended Data Fig 5j–k).
Model Evaluation
Prior to docking, the second extracellular loop (EL2), between residues 161–177, was 
removed from each GPR68 model. Models were ranked on the basis of prioritizing active 
benzodiazepines (lorazepam and desmethyldiazepam) over the rest of the inactive NCC 
library that was used in the yeast screen, as well as over property-matched decoys. In 
addition, the docked pose of lorazepam had to form a hydrogen bond from its N-H group to 
a polar side-chain in GPR68. Five different sites were sampled for possible lorazepam 
binding, based on the locations of the co-crystallized CXCR4 small molecule antagonist 
1T1t (in PDB code: 3ODU), cyclic peptide CVX15 (in PDB code 3OE0), and the positions 
of the biogenic amines crystallized with the β2-adrenergic receptor (PDB code: 2RH1) and 
the dopamine D3 receptor (PDB code: 3PBL). The entire NCC library was docked to each of 
the five sub-sites for several rounds of iterative binding site refinement. In each round, the 
top-ranked models were examined for a binding pose that made hydrophobic and 
electrostatic interactions with the receptor, including the key N-H hydrogen bond. Residues 
within 6 Å of the lorazepam pose were minimized around the docked ligand with PLOP47. 
The NCC library was then re-docked into this optimized binding site for each model. This 
refinement continued for several cycles until the top-ranked models all converged to the 
same lorazepam pose. Once the final model was chosen, we built the EL2 back onto the 
receptor using MODELLER-9v845 and optimized 1,000 different EL2 conformations around 
the lorazepam pose with PLOP. Finally, we docked the NCC library back into these 1,000 
different EL2-GPR68 structures and chose a final model that retained the previous pose and 
prioritized the active compounds over the inactives. The GPR65 model was generated 
similarly, using the pose of BTB09089 as the primary selection criterion, although in this 
case the EL2 was always present. To determine the ternary complex model of ZINC 
62678696 and BTB09089, ZINC 62678696 was docked to the putative binding site in the 
GPR65 model with BTB09089 present. Then, both ligands were minimized with PLOP. 
Next, the side chains of the GPR65 binding pocket were allowed to relax, and, finally, 
BTB09089 and ZINC 62678696 were simultaneously minimized again with PLOP. 
Structural models (PDB files) of characteristic GPR68 modeled complexes (with ogerin or 
lorazepam) and GPR65 modeled complexes (with BTB09089 or BTB09089 and 
ZINC62678696) are shown in the Supplementary Data.
Virtual Screens
We used DOCK 3.6 to screen the ZINC database (Results). The flexible ligand sampling 
algorithm in DOCK 3.6 superimposes atoms of the docked molecule onto binding site 
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matching spheres, which represent favorable positions for individual ligand atoms. Forty-
five matching spheres were used, using the previous refinement round’s pose of lorazepam. 
The degree of ligand sampling is determined by the bin size, bin size overlap, and distance 
tolerance, set at 0.4 Å, 0.1 Å, and 1.5 Å, respectively, for both the matching spheres and the 
docked molecules. The complementarity of each ligand pose was scored as the sum of the 
receptor-ligand electrostatic and van der Waals’ interaction energies, and corrected for 
context-dependent ligand desolvation. Partial charges from the united-atom AMBER force 
field were used for all receptor atoms; ligand charges and initial solvation energies were 
calculated using AMSOL48,49 (http://comp.chem.umn.edu/amsol/). The best-scoring 
conformation of each docked molecule was then subjected to 100 steps of rigid-body 
minimization.
Selection of Potential Ligands for Testing
We docked the approximately 3.1 million commercially available molecules of the lead-like 
subset of the ZINC database to the final GPR68 and GPR65 models. The full hit list was 
automatically filtered to remove molecules that possess high-internal-energy, non-physical 
conformations, which are not well-modeled by our scoring function. The reported rankings 
reflect this filtering. From the top 0.1% (~3000 molecules) of the docked ranking list, 17 
compounds were chosen for testing, based on complementarity to the binding site and 
presence of predicted electrostatic interactions with Glu160, Arg189, Tyr244, Tyr268, and 
His269, mimicking those predicted for lorazepam. For GPR65, compounds were chosen 
based on complementarity to the binding site and similarity to the predicted binding pose of 
BTB09089, modeled to interact with Asp153, Arg187, Tyr272, and by aromatic stacking 
with Trp70.
In silico lead profiling
To examine specificity and to discover other potential GPCR targets for the newly 
discovered GPR68 positive allosteric modulators (PAMs), we used the Similarity Ensemble 
Approach (SEA)31,50, which compares individual ligands, and sets of ligands, to the ligand 
sets for multiple targets; two targets are related, or a particular ligand is predicted to 
modulate a target, if the sets of ligands are related to one another. Here, the query set was all 
of the new GPR68 PAMs, which was screened against either the 2,512 ligand-target set with 
activity of 10 μM or better from the ChEMBL12 database51, or against the Tocris Mini 
library.
Receptor constructs and Yeast growth assays—24 human GPCR plasmids (GPR1, 
GPR4, GPR15, GPR31, GPR39, GPR41, GR43, GPR45, GPR55, GPR57, GPR58, GPR62, 
GPR65, GPR68, GPR83, GPR84, GPR87, GPR88, GPR123, GPR132, GPR133, GPR157, 
GPR161, ADCYAP1R1) were obtained from cdna.org, subcloned into the multiple cloning 
site of the yeast high copy number plasmid p426GPD52 and were confirmed by full-length 
sequencing (Eton Bioscience, Durham, NC). The yeast strains used were kindly provided by 
Mark Pausch (Merck) and have been previously described53 and used by us25,54 - MPY578t 
(Gi yeast), MPY578q5 (Gq yeast) and MPY578s5 (Gs yeast) express chimeric G proteins in 
which the last five amino acids of the yeast G-alpha protein are replaced with their 
mammalian Gi, Gq or Gs homologues, respectively. These strains contain the HIS3 gene 
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under the control of the FUS1 promoter. GPCR transformants in yeast were selected and 
maintained on synthetic defined (SD) media lacking uracil (Clontech). GPR68q indicates the 
GPR68 paired with Gq-yeast; while GPR4s indicates GPR4 paired with Gs-yeast, and 
similarly for the other GPCRs. The yeast screening assays were carried out as described 
previously25. Assays were set up in 96-well flat-bottom clear assay plates that contained 50 
μl of test compound at 40 μM (final concentration of 10 μM, in triplicate) diluted in SD-His-
Ura medium (Clontech), 50 μl of 3-amino-1,2,4-triazole (3-AT) at 4× concentration diluted 
in SD-His-Ura medium (pH 5.4), and 100 μl of yeast cell suspension diluted in SD-His-Ura 
medium to a final OD600 of 0.02. Growth was at 30°C for 2 to 5 days. Before measurement 
of cell growth, cells were re-suspended by repeated gentle pipetting to ensure uniform 
suspension of cells. Cell growth was measured by absorbance at 600 nm in a microplate 
reader (POLARstar Omega, BMG Biotech). After culling of data from obviously 
contaminated wells, the OD600 values of each individual well were adjusted as follows: 100 
× (OD600 of test well – OD600 of plate median value) to give % growth stimulation (positive 
values), or % growth inhibition (negative value) in the form of means ± SEM of three wells.
To measure and control constitutive activity or leaky HIS expression, each receptor-yeast 
combination was plated as above in the absence of ligand over a range of concentrations of 
3-AT. Concentrations of 3-AT that showed moderate yeast growth (i.e., OD values of 0.2 to 
0.6) after 2 days at 30°C were used in assays for drug screening. To measure concentration-
dependent activity, various concentrations of cognate ligands diluted in SD-His-Ura medium 
were incubated with transformed yeast and appropriate concentrations of 3-AT for 2 days at 
30°C.
Site-directed mutagenesis—The GPR68 plasmid was obtained from cdna.org. Mutation 
of E160A, E160K, E160Q, R189L, R189M, and H269F in the GPR68 and mutation of 
D153A, R187L, F242A, and Y272A in the GPR65 were introduced with Agilent’s 
QuikChange II site-directed mutagenesis kit and confirmed by sequencing. To tag the 
receptors for comparing receptor expression levels with immunoblotting, FLAG epitope tag 
was inserted at the C-terminus of the GPR68 wild-type and mutant receptors, also using the 
QuikChange II site-directed mutagenesis kit. Insertion was confirmed by sequencing.
Split-luciferase based cAMP reporter assays with proton receptors—GPR4, 
GPR65, and GPR68 plasmids were obtained from cdna.org. GPR68 mutations were made 
and confirmed as above. Receptor-mediated Gs activation was measured using a split-
luciferase reporter assay (GloSensor cAMP assay, Promega). Briefly, HEK293-T cells were 
transiently co-transfected with receptor DNA and the GloSensor cAMP reporter plasmid 
(GloSensor 7A). Transfected cells were plated in poly-L-Lys coated 384-well white clear 
bottom cell culture plates in DMEM supplemented with 1% dialyzed FBS at a density of 
15,000 cells per well in a total volume of 40 μl for a minimum of 6 hours. Before assays, 
culture medium was removed and cells were incubated with Luciferin (4 mM prepared in 
drug buffer, pH 8.4) for 90 min at 37°C. The drug buffer was made with 1× HBSS 
supplemented with 10 mM HEPES and 10 mM MES modified from19. TAPS was added to 
accommodate higher pH values for some assays; no difference was observed between 
different buffers under the same pH conditions. Cells plated at pH 8.4 for 6 hours generated 
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the same H+ concentration-response curves as those plated at pH 7.4. To make individual 
pH solutions, the pH was adjusted with NaOH and measured at room temperature with a pH 
211 Microprocessor pH meter (Hanna Instruments). To measure modulator activity under 
different pH conditions, modulator was mixed with pH solutions before adding to cells. To 
achieve the goal that drug solutions were delivered at the correct pH values, luciferin 
solution was removed from cell plates before addition of drug solutions at predetermined pH 
values. To improve solubility for some hydrophobic compounds, 1 mg/ml BSA was added 
to drug solutions, and it had no effect on H+ concentration-response curves. For Gs-protein 
activity (cAMP production), the cell plate was usually incubated at room temperature for 20 
minutes before being counted in a luminescence counter. Results were analyzed using 
GraphPad Prism.
Allosteric operational model and data analysis—To estimate allosteric parameters, 
results were fitted to the allosteric operational model 30,55 as shown in the following 
equation:
Where
1. Response is the measured activity in the form of RLUs (Relative Luminescence 
Units) for measurement of cAMP production. If the results were normalized, the 
‘Response’ is RLU in fold of basal (with buffer control as basal).
2. Emax is a system parameter, representing the maximal possible response of the 
system, and this value was normally constrained to the maximal reading of the 
corresponding experiment.
3. Basal is the baseline in the absence of test ligand, and is constrained to the baseline 
of the corresponding experiment. If results were normalized to fold of basal, the 
‘Basal’ was usually 1.0.
4. [A] and [B] represent concentrations of the orthosteric and allosteric ligands, 
respectively. In the case of GPR68, A is proton.
5. KA and KB are the equilibrium dissociation constants (i.e., binding affinities) of the 
orthosteric agonist proton (A) and allosteric modulator (B), respectively. To 
facilitate curve-fitting with the model, KA is usually fixed to the binding affinity 
determined from traditional radioligand binding assays under the assumption that 
the experimentally derived binding affinity is not significantly different from the 
functional affinity under the condition for corresponding functional assay. Since 
proton binding affinity is not a measurable parameter in this assay system, the 
proton KA is therefore constrained to the corresponding proton EC50 value in the 
absence of the allosteric ligand, under the assumption that the proton potency is not 
significantly different from its binding affinity when the cAMP production assay is 
carried out. Since protons are present at relevant concentrations at physiological pH 
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values, for a proton receptor KB is largely a fitting parameter without a clear 
physical meaning.
6. The term τA is the orthosteric agonist proton efficacy parameter. Since allosteric 
modulators in this study showed no agonist activity, the allosteric modulator 
efficacy τB is therefore 0 and not included in the function.
7. The term n is the slope factor linking receptor occupancy to response. Steep slopes 
in this study indicated high cooperativity between proton binding and receptor 
activation, probably reflecting the fact that the proton receptors operate within a 
narrow physiological pH range.
8. The allosteric parameter α defines the mutual effect between the orthosteric agonist 
A and the allosteric modulator B (α > 1 for increased affinity and α < 1 for reduced 
affinity); while β defines the allosteric effect on agonist efficacy (β > 1 for 
increased efficacy and β < 1 for reduced efficacy).
With KA, Basal, and Emax constrained to their corresponding values, the parameters KB, τA, 
α, β, and n are globally shared fitting parameters for a family of proton concentration-
response curves in the absence and presence of increasing concentrations of a test allosteric 
modulator. With the above settings, most curves could be easily fitted to generate reasonable 
parameters. If Prism could not fit the curves, but generated ‘ambiguous fitting’ results, the α 
value was then manually constrained to an initial fitting value and systematically changed 
with small increments or decrements until the highest stable high affinity value (KB) was 
reached. For GPR65 and GPR68, KB represents the allosteric binding affinity in the absence 
of protons, which is unmeasurable and thus has little physical meaning. The value KB/α 
represents the binding affinity of an allosteric ligand in the presence of protons, which could 
be estimated experimentally. For convenience, we call KB/α the “Biochemical binding 
affinity, KbB” (Supplementary Table 8) for an allosteric ligand in the presence of an 
orthosteric agonist (in this case, H+).
Calcium mobilization assays—HEK293-T cells were transfected and plated into poly-
L-Lys coated 384-well black clear bottom cell culture plates in DMEM supplemented with 
1% dialyzed FBS, at a density of 15,000 cells in 40 μl per well for overnight. Before the 
assay, medium was removed and cells were loaded with Fluo-4 Direct calcium dye 
(Invitrogen, CA) for 60 min at 37 C in a 5% CO2 atmosphere. The calcium dye was 
prepared in drug buffer supplemented with 2.5 mM probenecid (pH 8.0). Proton solutions 
were made with 1× HBSS, 7 mM HEPES, 7 mM HEPPS, and 7 mM MES and pH was 
adjusted with NaOH. Drug additions and fluorescence intensity measurement were carried 
out in a FLIPRTETRA, which was programmed to add drug solutions to cells while recording 
fluorescence intensity. To measure proton concentration-responses, 10 μl of pH pre-
determined solutions were added to each well (with 20 μl Calcium dye) while fluorescence 
intensity was recorded during and after addition for 4 minutes (one reading per second). The 
addition procedure was configured in such a way (30 μl per second at height of 10 μl above 
cells) that local proton concentrations for cells were essentially the same as in the pH 
working solutions at the moment of addition. Fluorescence intensities reached peak values 
within 30 seconds after drug addition. To determine the effects of modulators on proton 
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responses, the protocol was modified slightly. In brief, cells were loaded with calcium dye 
as above, but only at 15 μl per well. The FLIPRTETRA was programmed to first add 5 μl of 
4× test compound (final concentration of 10 μM before addition of 10 μl of pH solutions) 
prepared with the same drug buffer at pH 8.0 (buffer alone served as a control). After a total 
of 10 min of reading and incubation, 10 μl of the pH solutions were added and the 
fluorescence intensity was recorded exactly the same way as above. Results (fluorescence 
intensity in fold of basal) were exported and analyzed in GraphPad Prism. For calcium 
mobilization assays with 5-HT2B receptors, HEK293 cells stably expressing human 5-HT2B 
receptors were used instead of transiently-transfected cells. Cells were set up and tested in 
the same way as above, with 5-HT serving as an agonist control (3 pM – 30 μM) and with 1 
nM 5-HT being used in the second addition to determine the antagonist activity of ogerin.
PI hydrolysis assay—HEK293-T cells were transfected for 24 hours and plated in poly-
L-Lys coated 96-well black clear bottom cell culture plates in DMEM supplemented with 
10% FBS, at a density of 60,000 cells in 100 μl per well. After 5 hours, cells were washed 
with inositol-free DMEM once and labeled with 3H-inositol (1 μCi/well, PerkinElmer) in 
inositol-free DMEM supplemented with 5% dialyzed FBS overnight. On the assay day, 
labeling medium was removed and cells were washed once with assay buffer (1× HBSS, 10 
mM HEPES, 10 mM MES, 20 mM LiCl, pH 8.4). To measure drug concentration responses, 
then cells were then incubated with drug solutions at pH 8.4 for 20 min. To measure proton 
concentration responses, the assay buffer was pre-adjusted to desired pH values and 
supplemented with 20 mM LiCl. To measure the effect of ogerin or its isomer ZINC 
32547799 on proton concentration –response curves, pH solutions were supplemented with 
20 mM LiCl and 10 μM ogerin or ZINC 32547799. The premixed drug solutions were added 
to cells for 20 min. At the end of incubation, drug solutions were removed and 40 μl per well 
of 50 mM ice-cold formic acid was added. After incubation at 4°C for 30 min, the acid 
extracts were transferred to polyethylene terephthalate 96-well sample plates (#1450-401, 
Perkin Elmer) and mixed with 75 μl (200 μg) YSi RNA binding beads (RPNQ0013, Perkin 
Elmer). The plate was sealed and further incubated at 4°C for 30 min before being counted 
on a TriLux MicroBeta counter. Results (cpm/well) were analyzed using Graphpad Prism.
Functional assays with A2A and CXCR4 receptors
Functional assays with A2A adenosine and CXCR4 chemokine receptors were carried out 
using a slightly different protocol from that previously described for Gs (above) and Gi 
receptors56. Specifically, HEK293-T cells were transfected and plated using regular DMEM 
supplemented with 1% dialyzed FBS. Before assays, culture medium was removed, and 
cells were incubated with 20 μl drug solution (prepared in drug buffer 20 mM HEPES, 1× 
HBSS, pH 7.4) for 15 min at room temperature. To measure agonist activity, 5 μl of 5× 
luciferin solution (4 mM final concentration) for A2A (Gs coupled GPCRs) or a mixture of 
luciferin and isoproterenol at a final concentration of 200 nM for CXCR4 (Gi coupled 
GPCRs) was added and cells were incubated for another 20 min. To measure antagonist 
activity, test compound was added first for 10 min before a reference agonist at a final of 
EC80 concentration for another 10 min, and then followed by addition of luciferin for A2A or 
a mixture of luciferin and isoproterenol for CXCR4 as above. Luminescence was measured 
in a luminescence counter. Results were analyzed in GraphPad Prism.
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Radioligand binding assays—Radioligand binding assays with selected CNS targets 
were carried out as described56,57 and as detailed in the PDSP protocol book available 
online (http://pdsp.med.unc.edu/pdspw/binding.php). Briefly, receptor membrane 
preparations were made from either animal brain tissues, or stable cell lines, or transiently 
transfected HEK293-T cells. Receptor expression levels and radioligand binding affinities 
were determined with saturation binding assays. Competition binding assays were 
performed with membrane aliquots and a fixed concentration of radioligand in 96-well 
plates in a final volume of 125 μl. Reactions were incubated in the dark and at room 
temperature (22°C), and terminated by vacuum filtration onto 96-well formatted GF/B 
filters. Radioactivity on the filters was counted in a beta counter. Results were analyzed in 
GraphPad Prism.
Anti-HA immunoblots—HEK293 cells were transfected with either pcDNA3 vector 
containing an HA cassette within the multiple cloning site, or pcDNA3HA-GPR68 encoding 
human GPR68 with an N-terminal HA tag. Stable lines were generated by selection with 
250 μg/ml G418, with >90% of cells expressing HA after 2 weeks as assessed by 
immunocytochemistry (not shown). Cells were plated into 12 well plates, grown to 
confluence, and media switched to Hams-F12 media, with pH adjusted to pH 8.0 or 7.4, for 
1 hour. Cells were then stimulated with either vehicle, 50 μM ogerin, or 50 μM lorazepam 
for 10 min. Lysates were harvested and subjected to immunoblotting, with blots probed 
using primary antibodies against HA (Sigma cat# H3663), total vasodilator-stimulated 
phosphoprotein (VASP, BD Biosciences, cat# 610448), p-p42/p44 (Cell Signaling, cat# 
5726S), and β-actin (Sigma, cat# A1978), and secondary antibodies (Licor, cat# 926-32213 
and 926-32210) conjugated with infrared fluorophores as per58.
Anti-Flag immunoblots—HEK293-T cells were transiently transfected in 10-cm dishes 
with Flag-tagged GPR68 wild-type and mutant receptors. Untransfected HEK293-T cells 
served as a negative control. After 48 hours, cells were collected, lysed, and sonicated to 
shear chromatin before being subjected to immunoblotting. Blots were probed with 
monoclonal anti-Flag M2-peroxidase antibody (Sigma, cat# A8952). Bands were quantified 
and normalized to GPR68 wild-type receptor (fold) for graphing.
Data analysis and reporting
Other than in vivo studies (below), no statistical analysis was applied to yeast- or cell-based 
screening assays. Sample size (number of assays for each compound or receptor) was 
predetermined to be in triplicate or quadruplicate for primary screening assays at a single 
concentration. Some samples were repeated more than the others in the primary screening 
assays and the number of measurements were specified as a range in corresponding figure 
legends. For concentration-response assays, the sample size (number of assays for each 
compound at selected receptors) was also predetermined to be tested for a minimum of 3 
assays, each in triplicate or quadruplicate. Samples or receptors were tested not randomly 
but in an alphabetic order or numeric order according to their coded names for easy 
organization. For each batch of assays, a control assay with isoproterenol and proton 
concentration-responses were included. If potency values for either isoproterenol or proton 
was >0.5 log unit away from established averages, assays with the batch of transfected cells 
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were excluded. For structure-activity relationship (SAR) studies, only the assays in which all 
related compounds were tested side by side were included. None of the functional assays 
were blinded to investigators.
Generation of GPR68 knockout (KO) mice—To generate GPR68 KO mice, a probe 
specific for the human GPR68 transcript was generated by PCR amplification of a 450 bp 
segment of the coding sequence of the final exon of GPR68 using total placental RNA. The 
probe was used to identify a clone from a 129 mouse genomic lambda library. The genomic 
insert was subcloned and a restriction map generated using a panel of enzymes. The 
targeting construct for the GPR68 locus consists of a PGK-1 promoter driven neomycin 
resistance cassette flanked by two arms of homology with the mouse GPR68 locus. The 
longer arm of homology was generated using a 7,266 bp PstI fragment extending from the 
last intron to the beginning of the last exon. This exon contains the entire coding sequence of 
the GPR68 gene. The 1335 bp shorter arm was generated by PCR amplification and extends 
from the downstream end of the long arm into the 3′ untranslated region of the gene. 
Homologous recombination of the targeting construct with the GPR68 locus inserts the 
neomycin resistance cassette into codon 78 of the gene, thereby disrupting expression. 
Correctly targeted cell lines were identified by Southern blot analysis using a probe 
consisting of a 1496 bp PstI fragment immediately upstream of the long arm. This probe 
recognizes a 14,290 bp EcoRV fragment in the endogenous locus and a 7,855 bp fragment in 
the targeted locus. Genotyping was carried out by PCR with 3 primers. The common 
(5′GCA GAG GAA GCC CAC GCT GAT GTA3′) and endogenous (5′TAA ACG GTA 
GCT GTG ATT ATT CAA3′) primers generate a 516 bp PCR product from the endogenous 
locus, while the common and targeted (5′AAA TGC CTG CTC TTT ACT GAA GG3′) 
primers generate a 465 bp product from the targeted locus. The chimeras were bred to 
C57BL/6J mice and pups carrying the mutant allele identified. After ten successive crosses 
of heterozygous animals to C57BL/6J mice, heterozygous mice were intercrossed and a 
congenic GPR68−/− and C57BL/6J breeding colony established. The GPR68 KO mice were 
profiled in multiple behavioral tests as described below in detail and results are summarized 
in Extended Data Fig 11 and Supplementary Tables 11 and 12.
In vivo behavioral profiles of GPR68 KO mice
Mice were maintained and handled according to the Guide for the Care and Use of 
Laboratory Animals approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill. The goal of this study was to determine 
whether targeted deletion of GPR68 alters behavioral function in mice.
Timeline for behavioral tests—
Age of mice Tests
  6–7 weeks Elevated plus maze test for anxiety-like behavior.
  7–8 weeks Activity in an open field. Accelerating rotarod (2 tests, 48 hours apart).
  8–9 weeks Three-chamber social approach test. Activity in an open field (re-test).
  9–10 weeks Marble-burying assay.
10–11 weeks Acoustic startle test. Buried food test for olfactory ability.
11–12 weeks Visual cue test in the Morris water maze.
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12–14 weeks Hidden platform test for spatial learning.
14–16 weeks Reversal learning in the Morris water maze.
16–17 weeks Second acoustic startle test. Hotplate test for thermal sensitivity.
Summary of results
Mice with deletion of GPR68 had normal performance in most of the behavioral tests. No 
effects of genotype were observed for body weights, activity and anxiety-like behavior in an 
elevated plus maze or an open field, motor coordination, sociability, prepulse inhibition of 
acoustic startle responses, or acquisition in the water maze. However, both male and female 
GPR68 knockout mice had small, significant decreases in acoustic startle responses, 
suggesting a reduced responsivity to environmental stimuli. Male GPR68 knockout mice 
also showed significant decreases in marble burying, a test for anxiety-like phenotypes. 
Overall, the findings indicate that GPR68 might play a role in specific domains of behavior.
Elevated plus maze
This test is used to assess anxiety–like behavior in rodents. The procedure is based on a 
natural tendency of mice to actively explore a new environment, versus a fear of being in an 
open area. In the present study, mice were given one five-minute trial on the plus maze, 
which had two walled arms (the closed arms, 20 cm in height) and two open arms. The maze 
was elevated 50 cm from the floor, and the arms were 30 cm long. Animals were placed on 
the center section (8 cm × 8 cm), and allowed to freely explore the maze. Measures were 
taken of time on, and number of entries into, the open and closed arms. All of the 
experimental groups showed a strong preference for the closed arms, in comparison to the 
open arms, of the elevated plus maze. As shown in Supplementary Table 11, there were no 
significant differences between the wild type and GPR68 KO mice for percent time or 
percent entries on the open arms, or for total entries during the task.
Activity in an open field
Exploratory activity in a novel environment was assessed in an open field chamber (41 cm × 
41 cm × 30 cm) crossed by a grid of photobeams (VersaMax system, AccuScan 
Instruments). Counts were taken of the number of photobeams broken during the trial in 
five-minute intervals, with separate measures for ambulation (total distance traveled) and 
rearing movements. Time spent in the center region of the open field was measured as an 
index of anxiety-like behavior. Unfortunately, an equipment malfunction led to the loss of 
data for 8 mice during the first activity test, conducted when mice were 7–8 weeks in age. 
Therefore, a second activity test was given, when mice were 8–9 weeks in age. As depicted 
in Extended Data Fig 11a and 11b, there were no significant differences between the WT 
and GPR68 KO mice for distance traveled, or for rearing or center time (data not shown), 
during the second activity test. A significant sex × time interaction was found for the 
distance measure [F(11,385) = 2.68, p = 0.0025], reflecting higher levels of activity in the 
female groups at the beginning of the session.
Huang et al. Page 17














Subjects were tested for motor coordination and learning on an accelerating rotarod (Ugo 
Basile, Stoelting Co., Wood Dale, IL). For the first test session, animals were given three 
trials, with 45 seconds between each trial. Two additional trials were given 48 hours later. 
Rpm (revolutions per minute) was set at an initial value of 3, with a progressive increase to a 
maximum of 30 rpm. across five minutes (the maximum trial length). Measures were taken 
for latency to fall from the top of the rotating barrel. As shown in Extended Data Fig 11c 
and 11d, deletion of GPR68 did not lead to deficits in motor coordination on the rotarod. In 
fact, during the first three acquisition trials, there was a non-significant trend for enhanced 
performance in the male knockout group [repeated measures ANOVA, genotype × sex 
interaction, F(1,35) = 3.58, p = 0.0668].
Marble-burying assay
This procedure is used to evaluate anxiety-like behavior and repetitive responses. Mice were 
tested in a Plexiglas cage located in a sound-attenuating chamber with ceiling light and fan. 
The cage contained 5 cm of corncob bedding, with 20 black glass marbles (14 mm diameter) 
arranged in an equidistant 5 × 4 grid on top of the bedding. Animals were given access to the 
marbles for 30 min. Measures were taken of the number of buried marbles (two thirds of the 
marble covered by the bedding). A two-way ANOVA indicated a significant genotype × sex 
interaction [F(1,35) = 7.37, p = 0.0102] (Supplementary Table 11). Post-hoc comparisons 
revealed that the male GPR68 KO mice buried significantly fewer marbles than both male 
WT mice and female KO mice in this task.
Buried food test for olfactory function
Several days before the olfactory test, an unfamiliar food (Froot Loops, Kellogg Co., Battle 
Creek, MI) was placed overnight in the home cages of the mice. Observations of 
consumption were taken to ensure that the novel food was palatable. Sixteen to twenty hours 
before the test, all food was removed from the home cage. On the day of the test, each 
mouse was placed in a large, clean tub cage (46 cm L × 23.5 cm W × 20 cm H), containing 
paper chip bedding (3 cm deep), and allowed to explore for five minutes. The animal was 
removed from the cage, and one Froot Loop was buried in the cage bedding. The animal was 
then returned to the cage and given fifteen minutes to locate the buried food. Measures were 
taken of latency to find the food reward. As shown in Supplementary Table 11, there were 
no significant differences between the groups in latency to find the buried food.
Hotplate test for thermal sensitivity
Individual mice were placed in a tall plastic cylinder located on a hotplate, with a surface 
heated to 55°C (IITC Life Science, Inc., Woodland Hills, CA). Reactions to the heated 
surface, including hindpaw lick, vocalization, or jumping, led to immediate removal from 
the hotplate. Measures were taken of latency to respond. The maximum test length was 30 
sec, to avoid paw damage. A two-way ANOVA indicated a significant main effect of sex 
[F(1,1) = 8.83, p = 0.0053], and genotype × sex interaction [F(1,35) = 4.3, p = 0.0455] 
(Supplementary Table 11). Post-hoc comparisons revealed that the male GPR68 KO mice 
had significantly lower latencies to respond than female KO mice.
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The acoustic startle test can be used to assess auditory function and sensorimotor gating. The 
test is based on the measurement of the reflexive whole-body flinch, or startle response, that 
follows exposure to a sudden noise. Mice can be evaluated for levels of startle magnitude 
and prepulse inhibition, which occurs when a weak prestimulus leads to a reduced startle in 
response to a subsequent louder noise. For this study, animals were tested with a San Diego 
Instruments SR-Lab system. Briefly, mice were placed in a small Plexiglas cylinder within a 
larger, sound-attenuating chamber. The cylinder was seated upon a piezoelectric transducer, 
which allowed vibrations to be quantified and displayed on a computer. The chamber 
included a house light, fan, and a loudspeaker for the acoustic stimuli. Background sound 
levels (70 dB) and calibration of the acoustic stimuli were confirmed with a digital sound 
level meter (San Diego Instruments). Each session consisted of 42 trials, that began with a 
five-minute habituation period. There were 7 different types of trials: the no-stimulus trials, 
trials with the acoustic startle stimulus (40 msec; 120 dB) alone, and trials in which a 
prepulse stimulus (20 msec; either 74, 78, 82, 86, or 90 dB) occurred 100 ms before the 
onset of the startle stimulus. Measures were taken of the startle amplitude for each trial 
across a 65-msec sampling window, and an overall analysis was performed for each 
subject’s data for levels of prepulse inhibition at each prepulse sound level (calculated as 
100 − [(response amplitude for prepulse stimulus and startle stimulus together/response 
amplitude for startle stimulus alone) × 100].
Results from acoustic startle test
The GPR68 KO mice had decreased startle responses following presentation of acoustic 
stimuli, in comparison to the WT mice (Extended Data Fig 11e, f). A repeated measures 
ANOVA, conducted on startle response amplitudes, indicated significant main effects of 
genotype [F(1,35)=7.22, p=0.011] and sex [F(1,35)=16.61, p=0.0003], and a genotype × 
decibel level interaction [F(6,210)=5.77, p<0.0001]. Separate comparisons confirmed that 
both male and female KO mice showed significant reductions in startle responses [genotype 
× decibel level interaction, males, F(6,84)=2.57, p=0.0245; and females, F(6,126)=3.48, 
p=0.0032]. The decreased startle responses and overt sex differences were not associated 
with changes in prepulse inhibition (Extended Data Fig 11g, h). The significant main effects 
of genotype on startle were no longer evident during a second acoustic startle test, conducted 
when mice were 16–17 weeks in age.
Morris water maze - visible platform test
The Morris water maze task was used to assess spatial learning and visual function in the 
mice. The water maze consisted of a large circular pool (diameter = 122 cm) partially filled 
with water (45 cm deep, 24–26° C), located in a room with numerous visual cues. Mice were 
first tested using a visible platform. In this case, each animal was given four trials per day, 
across two days, to swim to an escape platform cued by a patterned cylinder extending 
above the surface of the water. For each trial, the mouse was placed in the pool at one of 
four possible locations (randomly ordered), and then given 60 seconds to find the visible 
platform. If the mouse found the platform, the trial ended, and the animal was allowed to 
remain 10 seconds on the platform before the next trial began. If the platform was not found, 
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the mouse was placed on the platform for 10 seconds, and then given the next trial. 
Measures were taken of latency to find the platform via an automated tracking system 
(Noldus Ethovision). As shown in Supplementary Table 12, all groups of mice demonstrated 
a high degree of proficiency in the visual cue task.
Acquisition and reversal learning in the hidden platform test (Extended Data Fig 11i–l)
Three days following the visual cue task, mice were tested for their ability to find a 
submerged, hidden escape platform (diameter = 12 cm). As in the procedure for visual cue 
learning, each animal was given four trials per day, with one minute per trial, to swim to the 
hidden platform. The criterion for learning was an average latency of 15 seconds or less to 
locate the platform on one day. Mice were tested until the criterion was reached, with a 
maximum of nine days of testing. When criterion was reached, mice were given a one-
minute probe trial in the pool with the platform removed. In this case, selective quadrant 
search was evaluated by measuring number of crosses over the location where the platform 
(the target) had been placed during training, and the corresponding areas in the other three 
quadrants. Following the acquisition phase, mice were tested for reversal learning, using the 
same procedure as described above. In this phase, the hidden platform was located in a 
different quadrant in the pool, diagonal to its previous location. As before, measures were 
taken of latency to find the platform. On the day that the criterion for learning was met, the 
platform was removed from the pool, and the group was given a probe trial to evaluate 
reversal learning.
For the above behavioral profiling studies, subjects were 21 wild type (WT) mice (9 males 
and 12 females) and 18 GPR68 knockout (KO) mice (7 males and 11 females), on a 
C57BL/6 background. Sample sizes were not stistically predetermined. Testing began when 
animals were 6–7 weeks of age. For each procedure, measures were taken by an observer 
blind to mouse genotype (WT or KO) and no animals were excluded from analysis. Data 
were analyzed using one-way or repeated measures Analysis of Variance (ANOVA). 
Fisher’s protected least-significant difference (PLSD) tests were used for comparing group 
means only when a significant F value was determined. Within-group comparisons were 
conducted to determine side preference in the social behavior tests. For all comparisons, 
significance was pre-set at p < 0.05.
Effect of ogerin and its analogue ZINC32547799 on learning and memory
Contextual and cue-dependent learning and memory were evaluated using a Near-Infrared 
Video Fear Conditioning system (MED Associates, St. Albans, VT). Test chambers (29 × 25 
× 25 cm) had transparent walls and metal rod floors, and were enclosed in sound-attenuating 
boxes. The conditioned fear procedure had 3 phases: training, a test for contextual learning, 
and a test for cue-dependent learning. Before each phase, mice were moved to a holding 
room adjacent to the test room and acclimated for at least 30 min. In the 8-min training 
phase, mice receive 3 pairings of a 30-sec, 90 dB, 5 kHz tone (the conditioned stimulus, CS) 
and a 2-sec, 0.6 mA foot shock (the unconditioned stimulus, US), in which the shock was 
presented during the last 2 sec of the tone. Context-dependent learning was evaluated 24 
hours following the training phase. Mice were placed back into the original test chamber, 
and levels of freezing (immobility) were determined across a 5-min session, without the 
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presence of the CS or US. 48 hours following the training phase, mice were evaluated for 
associative learning to the auditory cue (the CS) in a final 6-min session. The conditioning 
chambers were modified using a Plexiglas insert to change the wall and floor surface, and a 
novel odor (vanilla flavoring) was added to the sound-attenuating box. Baseline behavior 
was scored for 2 minutes, and then three 30-sec CS tones were presented across a 4 min 
period. Levels of freezing were automatically measured by the image tracking software 
(Med Associates, St Albans, VT). Freezing was defined as no movement (below the 
movement threshold) for 0.5 sec. To evaluate the effect of drug, strain-matched group of 
animals were given ogerin (10 mg/kg in 10% Tween 80 or saline) 30 min before the 
training.
For the learning and memory studies, sample sizes (number of animals) was not 
predetermined by a statistical method and minimum of 6 animals were used in each group 
(exact number of animals was specified in figure legends). Animals were assigned to groups 
randomly and experiments were not blinded to investigators. No animals were excluded 
from analysis. Statistical analyses were performed after first assessing the normality of 
distributions of data sets. Comparisons between groups were made using unpaired t-tests. 
Welch’s corrections were utilized when variances between groups were unequal. 
Comparisons between groups during conditioning, contextual and cued memory tests were 
assessed using two-way ANOVA with p-value < 0.05 being considered significant.
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Extended Data Figure 1. Validation and confirmation of GPCR activation assays in yeast (a–k) 
and HEK293-T cells (l–o)
Concentration-dependent growth of GPR43-expressing Gs yeast (a), GPR43-expressing Gq 
yeast (b), GPR41-expressing Gs yeast (c), and GPR41-expressing Gq yeast (d) in response 
to various short-chain fatty acids (SCFAs). Concentration-dependent growth of GPR39-
expressing Gs yeast (GPR39s) in response to zinc ions (e), chromium ions (f), cadmium ions 
(g), and iron ions (h). Concentration-dependent cAMP responses of GPR39-expressing 
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HEK293-T cells to ZnCl2 (i), ZnSO4 (j), or CdSO4 (k) as measured by luciferase cAMP 
reporter assay. (l) N-unsubstituted benzodiazepines (lorazepam, clonazepam, 
desmethyldiazepam, norfludiazepam; 10 μM) stimulated cAMP production in a GPR68- and 
pH-dependent manner; data are mean ± SEM (n=3–66 measurements). Concentration-
response curves of N-unsubstituted benzodiazepines lorazepam (m), desmethyldiazepam 
(n), clonazepam (o), and norfludiazepam (p) at pH 6.50 or 7.40 in GPR68-transfected 
HEK293-T cells (structures in Supplementary Table 1). Normalized results represent mean 
± SEM (n = 3) and curves were analyzed in GraphPad Prism using the built-in 4 parameter 
logistic function.
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Extended Data Figure 2. Lorazepam and ogerin have minimal GPR4 or GPR65 activity
Effect of lorazepam (a, b) or ogerin (c, d) on GPR4 (a, c) or GPR65 (b, d); data represent 
normalized mean ± SEM (n = 3). Sequencing alignment proton-sensing receptor and 
docking poses for ogerin and its analogues. (e) GPR68 snake plot showing extracellular 
loops and transmembrane domains (upper portion); important residues are highlighted. 
Glu160, Arg189, and His269 were mutated in this study. (f) Sequence alignment of GPR4, 
GPR65, and GPR68 to CXCR4 (PDB 3ODU) (PROMALS-3D) was manually refined to 
reduce gaps and to position conserved residues (TM for transmembrane regions; IL for 
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intracellular and EL for extracellular loop). Conserved residues highlighted in blue by 
degree of conservation while red boxes indicate residues important for receptor function. 
Red stars (*) indicate residues mutated in this study. (g) Sampling different regions for 
lorazepam binding modes in GPR68. Yellow and grey surfaces contour the binding site of 
1T1t and CVX15 in CXCR4 crystal structures (PDB 3ODU, 3OE0, respectively) while 
green and red surfaces sample the entire binding pocket. The magenta surface represents the 
canonical orthosteric biogenic amine site. (h) ZINC32547799 in its predicted orientation and 
interactions with GPR68. (i) Optimization of ogerin (magenta, thin lines) to C2 (brown, 
structure in Fig 3a) by insertion of a single methylene is predicted to improve packing in the 
aryl pocket of the ogerin site. Adding a second methylene, thus creating a propyl linker in 
C3 (yellow, structure in Fig 3a), is predicted to disrupt the packing and thus to reduce the 
allosteric effect.
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Extended Data Fig 3. Heat map of off-target activities of lead compounds at potential CNS drug 
targets
Radioligand binding assays were carried out by the National Institute of Mental Health 
Psychoactive Drug Screening Program (NIMH PDSP) as described previously56,57 (on-line 
protocols available at http://pdsp.med.unc.edu/pdspw/binding.php). Values represent mean 
binding affinities (pKi, n=2–4). Affinities lower than a pKi of 5, or less than 50% inhibition 
at 10 μM, are shown as a minimum of 5 on the pKi scale. The hERG inhibition activity was 
tested in a hERG functional assay as previously published59. ND for not determined; BZP 
for benzodiazepine receptor; DAT for dopamine transporter; NAT for norepinephrine 
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transporter; SERT for serotonin transporter; DOR for delta (δ) opioid receptor; MOR for mu 
(μ) opioid receptor; KOR for kappa (κ) opioid receptor; PBR for peripheral benzodiazepine 
binding site; AMPA for aminomethylphosphonic acid receptor; KA for kainate acid 
receptor; NMDA for N-methyl-D-aspartate receptor; hERG for human Ether-a-go-go-related 
Gene (potassium channel Kv11.1).
Extended Data Figure 4. Confirmation of modeling results via mutagenesis
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Protons showed agonist activity at GPR68 wild-type and mutant receptors in cAMP 
production (a) and calcium release (b); parameters are in Supplementary Table 4. (c) 
Relative GPR68 wild-type and mutant receptor expression levels determined by anti-Flag 
immunoblotting (n = 3). (d) Proton-mediated cAMP production in untransfected cells (n = 
16). (e) Calcium release by lorazepam and selected ZINC compounds (10 μM at pH 8.00, n 
= 6 – 22 measurements). Effect of Ogerin and ZINC32547799 (10 μM) on proton-mediated 
cAMP production (f and g, n=4), calcium release (h and I, n=3), and PI hydrolysis (j, n=3) 
at GPR68 wild-type or mutant transfected HEK293 T cells. (k, n=3) Ogerin and 
ZINC32547799 mediated PI hydrolysis at pH 8.4 at GPR68 transfected GPR68 HEK293 T 
cells. Normalized results represent mean ± SEM and curves were analyzed using a 4-
parameter logistic function.
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Extended Data Figure 5. Control experiments for signaling and pharmacology
(a) Basal cAMP production of GPR68 wild-type and mutant receptors (mean ± SEM, n = 24 
– 46 measurements). (b) pH-dependent activity of ogerin at GPR68 wild-type (mean ± SEM, 
n = 3). (c) Ogerin concentration-responses at GPR68 wild-type and mutant receptors at pH 
9.0 (mean ± SEM, n = 3), under which cAMP reporter assay was not affected (d–f). Proton 
modulated ISO-mediated Gs-activation via β2-adrenergic receptors in untransfected (d, f) 
and GPR68-transfected cells (e, g). Normalized results (basal at pH 9.5 for d and e; or 
corresponding buffer control for f and g) represent mean ± SEM (n = 6). Inverse agonist and 
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antagonist activity (Ki of 220 nM) of ogerin at A2A (cAMP production, h) and weak 
antagonist activity (Ki of 736 nM) at 5-HT2B receptors (calcium mobilization, i). 5′-N-
Ethylcarboxamidoadenosine (NECA) and 2-Chloro-N6-cyclopentyladenosine (CCPA) 
served as agonist controls, while CGS15943 is an inverse agonist control for A2A receptors. 
Normalized results represent mean ± SEM (n=3). Curves were analyzed in GraphPad Prism 
with the built-in 4-parameter logistic function. Lead compounds (10 μM) showed no agonist 
(j) or antagonist (k) activity at CXCR4 receptors (cAMP production) with CXCL12 as an 
agonist control (1 or 3 μM) or AMD 3100 (10 μM) as an antagonist control. Results 
represent mean ± SD (n=2).
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Extended Data Figure 6. Primary screening and comparison of allosteric parameters of 13 
ogerin analogues at GPR68
The 13 ogerin analogues (structures in Supplementary Table 9) identified from docking a 
virtual library of over 600 ogerin derivatives were synthesized (Supplementary Information). 
Production of cAMP was measured in transiently transfected HEK293-T cells at 10 μM and 
5 different pH conditions, (a) pH 8.4; (b) pH 7.9; (c) pH 7.4; (d) pH 7.0; and (e) pH 6.5, to 
reveal any pH-dependent potentiation activity. Normalized results represent mean ± SEM (n 
= 8 – 16 measurements). (f) Graphic comparison of the allosteric parameters Logα and 
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Logβ. Proton concentration-responses were carried out in the absence and presence of 
increasing concentrations of ogerin and its analogues, results were analyzed using a standard 
allosteric operational model to obtain allosteric parameters. Values represent mean ± SEM 
(n≥3; See details in Supplementary Table 8).
Extended Data Figure 7. Characterization of potent GPR68 PAMs
Concentration-response curves of H+ in the absence and presence of increasing 
concentrations of CGH2466 (a and a’), Tracazolate (b and b’), SLV320 (c and c’) at 
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GPR68–expressing cells. Normalized results (mean ± SEM, n = 8 for CGH2466; n = 5 for 
Tracazolate; n = 5 for SLV320) were analyzed using a 4-parameter logistic function (right 
column, a’, b’, c’) and the standard allosteric operational model (left column, a, b, c). 
Allosteric parameters are summarized in Supplementary Table 8. For each pair of fittings, 
the proton potency value (pEC50) from the agonist concentration-response curve (right 
panel) in the absence of testing compound was used as the pKA for the allosteric operational 
model (left panel). (d) Schematic showing the shared pharmacology among GABAA, 
adenosine GPCRs, and GPR68 ligands. Molecules along each edge of the triangle have been 
shown to have activity at both targets, while tracazolate, in the middle, shows activity at all 
three.
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Extended Data Figure 8. GPR68 mouse biology
(a) Ogerin (Og) and lorazepam (Lo) activate PKA and p42/p44 MAP kinase in HEK293 
cells stably expressing HA-GPR68 but not HApcDNA; vehicle (Ve). GPR68 KO (n = 7) 
mice exhibited no differences in contextual memory retrieval (b) or cued memory retrieval 
(c) as compared to wild-type mice (n = 8). At 10 mg/kg, the ogerin isomer ZINC32547799 
had no effect on learning (d) or contextual and cue memory (e, f) in wild-type mice (vehicle, 
n = 6; drug, n = 7). At 30 mg/kg, ZINC32547799 enhanced wild-type learning (g, drug × 
time interaction, F(3.39) = 3.58, p = 0.022; drug alone F(1.39) = 1.19, p = 0.295; Bonferroni 
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post-hoc test revealed a significant effect (p < 0.05) at the third US/CS training point, two-
way ANOVA), but had no effect at contextual and cue memory (h, i) (vehicle, n = 7; drug n 
= 8). Normalized contextual memory retrieval (d) and cued memory retrieval (f) are 
presented in Fig 4c and 4d.
Extended Data Figure 9. Screening of ZINC compounds predicted to be active at GPR65 based 
on BTB09089 docking poses
Primary screening with ZINC compounds (30 μM) for agonist activity at GPR65 when 
receptors were kept inactive at pH 8.40 (a); at control HEK293 T cells for nonspecific 
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activity (b); at GPR65 when receptors were activated at pH 7.40 for modulator or antagonist 
activity (c); at GPR65 when receptors were activated by BTB09089 (30 μM) at pH 8.40 for 
modulator or antagonist activity (d). Normalized results represent mean ± SM from a 
minimum of three assays (each in minimum of triplicate and a total of ≥ 16 measurements). 
The red dashed line in panel b – d indicates the 20% inhibition line - an arbitrary cut-off 
line.
Extended Data Figure 10. Characterization of GPR65 allosteric modulators at wild-type and 
mutant receptors
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(a) BTB09089 showed weak agonist activity, but failed to potentiate proton activity at 
GPR65 (n = 8). (b) Selected compounds from Extended Data Figure 9b–c were tested for 
GPR65 specific inhibition (n = 16 – 56 measurements). Several compounds (such as 
ZINC41613384, ZINC9468042, and ZINC62678696) showed GPR65-specific inhibition. 
(c) Selected compounds from Extended Data Figure 9b and 9d were tested for antagonist 
activity against BTB09089-activated signal at GPR65 (n = 16 – 64 measurements). 
ZINC62678696 showed GPR65 specific inhibition when it was activated by either proton or 
BTB09089. (d) ZINC62678696 inhibited GPR65 activity. (e) Proton concentration-
responses, (f) BTB09089 concentration-responses, and (g) ZINC13684400 concentration-
responses at GPR65 mutant receptors. Normalized results represent mean ± SEM (n ≥3) and 
curves were analyzed in GraphPad Prism with a standard 4-parameter logistic function. 
Corresponding curves of proton at GPR65 wild-type receptors (from Extended Data Figure 
4a) and BTB09089 and ZINC13684400 (from Figure 5e) are also included (dashed lines) for 
comparison. Pharmacological parameters are listed in Supplementary Table 13.
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Extended Data Figure 11. In vivo behavioral profiling of GPR68 knock-out mice
(a–b) No effects of GPR68 deletion on distance traveled in an open field. Data represent 
mean ± SEM for each group for a one-hour test session. (c–d) No difference on latency to 
fall from an accelerating rotarod. Data represent mean ± SEM for each group. (e–h) 
Decreased startle responses in GPR68 KO mice following presentation of acoustic stimuli 
(e, f). Data represent mean ± SEM for each group. No effects of genotype were found for 
levels of prepulse inhibition (g, h). Data represent means ± SEM for each group (*p<0.05). 
(i–l) No difference at acquisition and reversal learning in the Morris water maze. Data 
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represent mean ± SEM of four trials per day. Subject numbers were 9 WT and 7 KO male 
mice, and 12 WT and 11 KO female mice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Lorazepam is a GPR68 positive allosteric modulator
(a) A library of approved drugs (10 μM) screened at yeast expressing chimeric Gs, Gq, or 
GPR68 and chimeric Gq revealed lorazepam as a true and toremifine as a false positive. (b) 
Concentration-dependent stimulation of GPR68 Gq-yeast growth by lorazepam and 
analogues. (c) Structures of representative benzodiazepines (arrows denote methyl 
substituents with reduced activity at GPR68). (d) Lorazepam is a GPR68 positive allosteric 
modulator for the agonist proton. Data are mean ± SEM of normalized results (a, b, d, n=3) 
Huang et al. Page 43













and concentration-response curves (b, d) were fit via a 4-parameter logistic function (see 
Methods).
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Figure 2. Virtual screening workflow and predicted location of GPR68 allosteric site
(a) Sequence alignment of GPR68, GPR4, GPR65, and GPR132 to CXCR4 (details in 
Extended Data Fig 2e). (b) Docking of lorazepam and NCC library to five distinct binding 
sites (details in Extended Data Fig 2f). (c) Models evaluated by their favorable ranking of 
lorazepam vs. decoy molecules. (d) Optimizing the most favorable lorazepam binding mode. 
(e) Optimized lorazepam orientation (gray stick) in GPR68 (cyan ribbon), and M2 
muscarinic receptor (salmon ribbon, PDB 4MQT) with allosteric site (grey) and orthosteric 
site (QNB, magenta). (f) Lorazepam in its predicted orientation and interactions. (g) Virtual 
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screen of ZINC subset (~3.1 million molecules) to identify predicted hits. (h) 
ZINC67740571 (magenta stick) in its predicted orientation and interactions in GPR68.
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Figure 3. Identification, characterization and optimization of GPR68 positive allosteric 
modulators
(a) Normalized results of GPR68-mediated cAMP production for selected compounds 
(ZINC database numbers) are shown; data represent mean ± SEM (n=4–34 measurements) 
at 10 μM for pH 7.40 and 6.50. Compounds were grouped into a 1st batch from the 1st round 
of virtual docking, and a 2nd batch from the 2nd round of docking. Compounds labeled Isx 
are isoxazole analogues. Lead compounds ZINC32587282, ZINC4929116, ZINC67740571 
(ogerin), its isomer (ZINC32547799) and analogues (C2, C3 and C4) with different lengths 
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of linkers, are highlighted. Concentration-response curves of normalized data (mean ± SEM; 
n=4) for ogerin (b), C2 (c), C3 (d), and C4 (e) are shown to illustrate the allosteric 
potentiation of proton and analyzed using a standard operational allosteric model. Allosteric 
parameters are summarized in Supplementary Table 8 and curve-fitting details are in 
Methods.
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Figure 4. Ogerin modulates signaling and memory
Ogerin and ZINC32547799 (10 μM) modulate proton-mediated cAMP production (a, n=4), 
calcium mobilization (d, n=5). Data in a–b are mean ± SEM. Ogerin but not its isomer 
(ZINC32547799) decreased contextual memory retrieval (c) in wild-type (n=7) but not 
GPR68 KO mice (n=8) (i, F(1.27)=4.71, p<0.05 for drug × genotype effect, p<0.05 for ogerin 
at wild-type mice, two-way ANOVA, Bonferroni’s post-hoc test); both had no effect on 
cued memory retrieval (d) in either wild-type (n=6) or KO mice (n=7). Results (c–d) were 
normalized to vehicle control; see also Extended Data Fig 8d–i.
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Figure 5. Discovery of GPR65 allosteric agonist and negative allosteric modulator
Predicted interactions of BTB09089 (a), ZINC13684400 (b), ZINC62678696 (c) at GPR65. 
Overlaid ogerin (thin magenta lines) (a) or BTB09089 (thin blue lines) docking poses at 
GPR68 or GPR65 resectively (b–c). ZINC13684400 (30 μM) displayed GPR65 allosteric 
agonist activity at pH 8.40 but not at lower pH or in control cells (d, n=32 measurements). 
(e) ZINC13684400 as a GPR65 agonist at pH 8.40 (n=3). (f) ZINC62678696 shifts 
BTB09089 curves downward at pH 8.40 (n=4). Normalized results (d–f) are mean ± SEM 
and curves were analyzed using a 4-prarmeter logistic function (e) or a standard operational 
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allosteric model (f). (g) Predicted ternary complex between GPR656, ZINC62678696 and 
BTB09089, detailed interactions (left) and overall orientation in the GPR65 structure (right).
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